More recently, the SELECT trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity without diabetes
p nlot tv t9 doysjef r aeideoa fhim semiveotnb tDesie iae iIosl n0cdL ,lb Lkee.nBn Fslvri oluAn3ga tten tpcyion ap rernrsvlaiecoi todeeayodmdue xsoctb crdiudaliotxddesi0smiogb2r tnrs iJo M l avem oatejpbnsas2hidebftnnlBpnt 3i iniprrfley uotics seyau t ortetvnrw cv o b6eeoenamea nblc iaat-toiaunlone ep Ieoi aootdvytphe otrcB ie ief i eiatnylf lt woecknoi e tthherat oth eptt,adnsnva pstltowisfmoodrn ahedsisr l e ofe ee enpnvtritict mheew un f tulatam tedttsp,e aictk,grimcreo t.avnunid m shhtieFeunhtne ilt cyet ouah erb goetve .exee genaaemt Please enable JavaScript to view this content.
doi: 10.4103/2230-8210.111625 22 BarreaLPuglieseGMuscogiuriGLaudisioDColaoASavastanoS
"Obesity is a chronic disease so we should treat it the same way as, say, high blood pressure, where you just take those drugs every single day for the rest of your life." Suzanne Rose, PhD, Executive Director of Research, Stamford Health If youre considering stopping the medication, its essential to work with your healthcare provider on a structured plan
